Brokerages Set Personalis, Inc. (NASDAQ:PSNL) Target Price at $14.25

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $14.25.

PSNL has been the subject of several recent research reports. Morgan Stanley raised their price target on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. TD Cowen reiterated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Zacks Research cut Personalis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 435,032 shares of company stock valued at $5,599,929 in the last quarter. 4.20% of the stock is owned by insiders.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in Personalis during the 4th quarter worth $31,000. Legal & General Group Plc acquired a new stake in Personalis during the 2nd quarter worth $30,000. Quantbot Technologies LP purchased a new stake in Personalis in the second quarter valued at $69,000. Finally, BNP Paribas Financial Markets lifted its position in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Trading Up 1.4%

PSNL stock opened at $14.21 on Friday. The business’s fifty day moving average price is $12.58 and its 200 day moving average price is $9.42. Personalis has a 12-month low of $4.44 and a 12-month high of $16.39. The company has a market capitalization of $1.49 billion, a PE ratio of -13.04 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Research analysts predict that Personalis will post -1.07 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.